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man capital, incidence, and prevalence were chosen for
review based on their relevance.
RESULTS: Preliminary results indicate that the published
cost studies available underestimate the "true" costs of
smoking. The most current articles approximate annual
direct medical costs to health care payers of $50 billion
(1993); inflating to 1997 equals $59 billion or $1,200 per
smoker. Although the latest cost studies do not attempt
to estimate indirect costs, past studies have found indirect
costs to be 1.5-2 times the direct costs. Therefore, using
direct and indirect costs we estimate total smoking costs
to be $150 billion (1993); inflating to 1997 equals $176
billion or $3,500 per smoker.
CONCLUSION: Quantifying the cost of smoking is a
difficult task due to tobacco use infiltrating many aspects
of life and the dependency of cost on perspective. Cost-
of-illness studies provide cost estimation data which can
be useful in aiding decision-makers who are allocating
health care resources.
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Recent lipid therapy clinical trials confirm the treatment
recommendations of the National Cholesterol Education
Program (NCEP) and extend the proven benefits of pri-
mary and secondary prevention to women, elderly, and
high risk patients with average cholesterol.
OBJECTIVE: The purpose of this study was to estimate
and compare the size of the primary and secondary pre-
vention population if lipid treatment recommendations
were based on (1) the NCEP treatment guidelines and the
baseline characteristics of (2) the primary prevention
population in the West of Scotland Coronary Prevention
Study (WOSCOPS) and the Air Force/Texas Coronary
Atherosclerosis Prevention Study (AFCAPS), (3) the sec-
ondary prevention population in the Cholesterol and Re-
current Events (CARE) trial, and the Scandinavian Sim-
vastatin Survival study (4S).
METHODS: Phase 1 data from the third National
Health and Nutrition Examination Survey were used for
analysis.
RESULTS: Following the current NCEP recommenda-
tions, 18.6 and 5.8 million adults would be candidates
for primary prevention and secondary prevention inter-
vention, respectively. If the treatment guidelines were
based on the characteristics of the WOSCOPS or AF-
CAPS patients, the size of the primary prevention popula-
tion would increase by 12.2 million to 30.8 million. Ex-
tending the recommendation based on the characteristics
of the CARE or the 4S study patients would increase the
secondary prevention population size by 2 million to 7.8
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million.
CONCLUSION: Recent clinical trials suggest that more
than 15% of U.S. adults would benefit from lipid-lower-
ing therapy for primary and secondary prevention of
heart disease. Cost-effectiveness evaluation of lipid-low-
ering strategies should be used as a guide to treatment
decisions.
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The impact of acute renal failure (ARF) on cost was evalu-
ated in elderly patients with congestive heart failure (CHF).
METHODS: We reviewed medical records of 2,176 Con-
necticut Medicare beneficiaries, aged 65 and older who
were hospitalized with CHF, excluding CHF due to se-
vere AS, MS, or primary non-cardiac illness, between
January 1994 and December 1995 at 20 hospitals. ARF
was defined as an increase in serum creatinine level of
25% from admission, to at least 2 mg/dL during hospital-
ization. We excluded patients who did not have at least
two creatinine measurements (N = 251). To avoid in-
cluding patients with ARF as a result of procedures or
complications, we excluded all patients with major com-
plications or procedures during hospitalization (n =
531). Linear regression models were used to examine the
relationship between ARF and length of hospital stay and
hospital cost.
RESULTS: A total of 1,681 patients were included in the
study sample. Of those, 164 (10%) developed ARF dur-
ing hospitalization. After adjusting for confounding ef-
fects of sex, age, history of CHF, history of hypertension,
diabetes, rales, hematocrit, creatinine, systolic blood
pressure, and left ventricular ejection fraction, ARF was
associated with a significant increase in the length of stay
(LOS) by 3.31 days (p < 0.0001) and a significant in-
crease in hospital cost by $2,714 (p < 0.0001).
CONCLUSION: ARF in hospitalized older patients with
CHF is associated with a longer LOS and higher cost.
Strategies to prevent the development of ARF in high-risk
hospitalized patients may provide the opportunity for
marked reductions in cost.
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OBJECTIVE: To calculate the cost of heart failure in Bel-
gium, based on an epidemiological model.
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METHODS: We applied a state transition model to sim-
ulate the disease progression of heart failure over a period
of 5 years, taking into account a weighted average of cur-
rent practice. Costs related to current practice (1996 val-
ues) and disease progression were taken from the per-
spective of the health insurance. Unit costs of ambulatory
care were collected through official listings; hospitaliza-
tion costs for heart failure were collected from a database
of 58 hospitals (ICD codes 402, 428, 429). Current prac-
tice was obtained through review of 250 patient records
in primary care, starting on the day of initiating therapy
up to 6 months later, and through expert interviews (2
rounds Delphi method).
RESULTS: The model indicates that the expected cost of
treating heart failure in 1996 in Belgium was 318,000 Bef
over 5 years, for an average number of life years of 3.59.
ACE inhibitors are used in 34% of patients but are
mostly applied only in higher NYHA classes (more ill pa-
tients), although studies recommend to prescribe those
drugs earlier in the disease development, since they can
avoid morbidity (hospitalisation) and mortality. We cal-
culated that starting earlier with ACE inhibitors and dou-
bling their use would increase the total costs to 351,700
Bef for an extra survival time of 0.07 life years.
CONCLUSIONS: The study showed that state transition
models can be applied in the assessment of the manage-
ment of heart failure. Changes in the management should
be expressed in extra costs per extra life year and com-
pared to interventions in other disease areas.
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Bolus formulations of new thrombolytic agents for the
treatment of acute myocardial infarction (AMI) may offer
benefits in efficiency of administration, door-to-needle
time, quality improvement, and costs.
METHODS: A telephone survey of 23 experienced emer-
gency room (ER) staff at community and urban hospitals
encompassed the "hassle" involved with thrombolytic
administration. Nurses were asked to compare a hypo-
thetical single bolus with an infusion formulation of rt-PA
under assumptions of equal efficacy and safety. A "has-
sle" analysis examined the differences in aspects such as
protocol complexity, interference with other tasks, poten-
tial for error, and training requirements.
RESULTS: In all aspects, bolus injection was associated
with significantly less hassle than infusion (p < .001). In
particular, bolus injection was perceived as less problem-
atic for nurses in terms of following the protocol, inter-
ference with timely performance of other tasks, distrac-
tion from other tasks, and hassle associated with the
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thrombolytic procedure. The results also suggested that
bolus injections may reduce door-to-needle time.
CONCLUSION: A single bolus thrombolytic may offer
promise for improved ease of care, quality patient man-
agement, and incremental reductions in door-to-needle
time. Direct observational studies are needed to more
precisely measure the potential reductions in door-to-nee-
die time using bolus injection.
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In developing an economic model of type 2 diabetes mel-
litus, the costs associated with its complications were ex-
amined. This presentation focuses on the first year costs
associated with acute myocardial infarction (MI).
OBJECTIVE: To estimate the first year costs of initial
acute care (accommodation, procedure and ancillary hos-
pital charges and MD fees) and subsequent care (rehabili-
tation, nursing home, home health care, physician visits,
lab, medications, surgical and invasive cardiovascular
procedures occurring post-discharge) accrued in the man-
agement of MI in diabetic patients.
METHODS: Estimates for these costs were developed
based on data from five all payer, acute care, state dis-
charge databases (CA, FL, MA, MD, NC) and MA long
term care data, using ICD9 codes to identify disease and
procedure level data. These sources were supplemented
by fee schedules, other agency and survey data and the
literature. The proportions of patients consuming each
type of subsequent resource use were estimated from dis-
charge data for each population and published literature.
All costs are reported in 1996 US$, adjusted appropri-
ately for medical inflation and cost-to-charge ratios.
RESULTS: Approximately 31,000 discharges of diabetic
patients with a principal diagnosis of AMI were identi-
fied. The initial hospitalization was 7 days, on average,
with a mean cost of $16,520. The case fatality rate in
hospital was 11 %, and 38% received some type of subse-
quent care post-discharge. Thus, hospitalization ac-
counted for 60% of the total average first year costs
($27,630) accrued.
CONCLUSION: Increased medical management resulting
from an MI, which continues beyond the first year, adds a
substantial cost burden. Avoidance of macrovascular com-
plications should be a key goal of diabetes management.
